How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack?

被引:92
作者
Mouradian, MS
Majumdar, SR
Senthilselvan, A
Khan, K
Shuaib, A
机构
[1] Univ Alberta, Dept Med, Div Neurol, Walter C Mackenzie Hlth Sci Ctr 2E313, Edmonton, AB T6G 2B7, Canada
[2] Univ Alberta, Dept Med, Div Gen Internal Med, Edmonton, AB T6G 2B7, Canada
[3] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB T6G 2B7, Canada
关键词
secondary prevention; stroke prevention;
D O I
10.1161/01.STR.0000017877.62543.14
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Stroke prevention clinics (SPCs) are not usually involved with the active management of hypertension, hyperlipidemia, diabetes, and smoking. The effect of consultations generated at SPCs on the adequacy of the management of these risk factors for stroke has not been well described, and few studies have long-term follow-up. Methods-We performed a prospective study of 119 consecutive patients referred to an SPC for secondary prevention. One year after their baseline visit, patients were re-evaluated for the adequacy of the management of the above risk factors, and the proportion of improvement was assessed. Results-One-hundred twelve patients returned for their 1-year follow-up visit. Sixty-six were male, and the average age was 65 years. Hypertension was present in 83 patients, hyperlipidemia in 92, diabetes in 26, and smoking in 38, and 80 had multiple risk factors. At baseline, 66% of patients with hypertension, 17% of patients with hyperlipidemia, and 23% of diabetics had adequate management of their respective risk factors. During 1 year of follow-up, hypertension management improved 20% (P<0.001) and lipid management improved 32% (P<0.001). There was no significant improvement in diabetes management or smoking cessation. Conclusions-Although our understanding of the benefit of addressing hypertension, hyperlipidemia, diabetes, and smoking for secondary prevention of stroke is evolving, we found marked room for improvement in the management of these four risk factors. SPCs may need to be more actively involved in the management of these modifiable risk factors, if we are to significantly impact the risk of recurrent stroke.
引用
收藏
页码:1656 / 1659
页数:4
相关论文
共 32 条
[1]   Antithrombotic therapy in atrial fibrillation [J].
Albers, GW ;
Dalen, JE ;
Laupacis, A ;
Manning, WJ ;
Petersen, P ;
Singer, DE .
CHEST, 2001, 119 (01) :194S-206S
[2]  
[Anonymous], 1991, Lancet, V338, P1345
[3]  
Byington RP, 2001, CIRCULATION, V103, P387
[4]  
Callahan A, 2001, AM J CARDIOL, V88, p33J
[5]  
COLLINS R, 1999, STROKE, V30, P1304
[6]   European stroke prevention study .2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke [J].
Diener, HC ;
Cunha, L ;
Forbes, C ;
Sivenius, J ;
Smets, P ;
Lowenthal, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1996, 143 (1-2) :1-13
[7]   THE UNITED-KINGDOM TRANSIENT ISCHEMIC ATTACK (UK-TIA) ASPIRIN TRIAL - FINAL RESULTS [J].
FARRELL, B ;
GODWIN, J ;
RICHARDS, S ;
WARLOW, C .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1991, 54 (12) :1044-1054
[8]   Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European carotid surgery trial (ECST) [J].
Farrell, B ;
Fraser, A ;
Sandercock, P ;
Slattery, J ;
Warlow, CP .
LANCET, 1998, 351 (9113) :1379-1387
[9]   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339
[10]  
GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015